Unknown PHASE4 INTERVENTIONAL NCT00354445

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement

Sponsor: Eyetech Pharmaceuticals

Conditions Age-Related Macular Degeneration (AMD)

Interventions pegaptanib sodium (Macugen)

Updated 5 times since 2017 Last updated: Jan 12, 2007 Started: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Age-Related Macular Degeneration (AMD), this trial is ongoing. The trial is conducted by Eyetech Pharmaceuticals and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eyetech Pharmaceuticals
Pfizer

Data source: Eyetech Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Abilene, United States